Welcome
Support Centre
12 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ ...Back to search results ] [ Print-friendly version ]
Role of exercise and diet in disuse atrophy in hip surgery patients
ISRCTN ISRCTN32820033
ClinicalTrials.gov identifier
Public title Role of exercise and diet in disuse atrophy in hip surgery patients
Scientific title The role of pre-surgery training and protein supplementation in the mitigation of disuse muscle atrophy in patients undergoing elective hip arthroplasty.
Acronym N/A
Serial number at source N/A
Study hypothesis The normal loss of skeletal muscle mass and strength associated with old age (sarcopenia) poses a particular risk to the elderly when affected by illness or injury resulting in a period of immobilisation. Such situations, including immobilisation due to hip-fracture surgery are common amongst the elderly population. The resulting disuse atrophy, particularly of the skeletal muscle of the lower limb, is a large contributing factor to the poor rehabilitation and high morbidity and mortality associated with incidences such as hip fracture. It has been shown that essential amino acid supplementation can stimulate muscle protein synthesis in both elderly individuals and young volunteers subject to conditions of chronic unloading. Furthermore, as skeletal muscle retains its capacity for adaptation into old age there is increasing evidence that older, as well as younger individuals can limit and even reverse to a certain degree atrophy associated muscle weakness by inducing neuromuscular and tendinous adaptations with resistance strength training programs.
At present, the limited previous research into the effects of chronic unloading in the elderly make it difficult to determine the extent with which reduction in muscle mass or decreased levels of physical activity are responsible for the characteristic loss of muscle strength associated with old age. Further research is necessary to examine the relationship between muscle function and chronic disuse to address this problem. It has been shown that knee and hip arthroplasty patients with better preoperative quality of life and physical function have less pain and better postoperative physical function than those with a lower level of preoperative physical activity. Combining preoperative strength training and essential amino acid (leucine) supplementation may increase muscle strength and function and as a result may mitigate the loss of muscle mass, hence increasing preoperative physiological reserve, potentially improving speed and extent of recovery of elderly patients following surgery.
Lay summary
Ethics approval The ethics application will be submitted to NHS Research Ethics Committee
Study design Single centre double blind placebo controlled longitudinal study
Countries of recruitment United Kingdom
Disease/condition/study domain Sarcopenia
Participants - inclusion criteria 1. Elderly patients (60+ years), males and females, awaiting elective total hip arthroplasty but otherwise in relatively good health
2. Participants must have a good understanding of English to understand verbal explanations and written information given in English
3. Participants must be able to give fully informed consent
Participants - exclusion criteria All participants will be screened by a physician and will be excluded from the study if they suffer from or have ever suffered from
1. Previous stroke
2. Uncontrolled cardiovascular disease
3. Motor neurone disease
4. Parkinson's disease
5. Medically diagnosed osteoporosis
6. Type II diabetes
7. Hypertension or myocardial infarction within the previous two
years
8. Acute febrile or systemic disease within the past two years
9. Currently taking beta blockers
Anticipated start date 01/01/2011
Anticipated end date 31/12/2011
Status of trial Completed
Patient information material Not available in web format, please use contact details below to request a patient information sheet
Target number of participants 45
Interventions Interventions will consist of resistance training programs combined with essential amino acid (leucine) supplementation or non-essential amino acid (alanine) supplementation for 10 weeks, pre-surgery.

Participants in the training groups will be supplied with Thera-band® resistance exercise bands and instructed on how to perform resistance exercises aimed to build up and strengthen the knee extensor (quadriceps femoris) muscles. Participants will be asked to train 3 times weekly at home and will keep regular exercise diaries so exercise regimes can be monitored. Participants will also be contacted throughout the training period to ensure exercises are completed properly and to provide an opportunity for participants to ask any questions or resolve any issues they may have during the training. Participants will train for 10 weeks while awaiting surgery.

Participants will be asked to take daily oral suspensions containing either an essential amino acid, commercially available leucine (0.6g/kg body weight) (isolated from cow’s milk) or placebo, a non-essential amino acid alanine (same dosage). All participants will be asked to stop taking any nutritional supplementation at least one month before the study begins. Participants will be asked to take essential amino acid and placebo supplements once daily but not within 1 hour before or after resistance training during the training period.

The total duration of follow up will be 3 months post surgery.
Primary outcome measure(s) 1. Muscle thickness and architecture, measured by ultrasound
2. Muscle strength, measured by dynamometer
These outcomes will be assessed at baseline (10 weeks prior to surgery), immediately prior to surgery, and at 1 and 3 months post surgery.
Secondary outcome measure(s) None
Sources of funding 1. EU Seventh Framework Programme (FP7) (Europe)
2. Institut National de la Sante et de la Recherge Medicale (INSERM) (France)
Trial website
Publications
Contact name Miss  Emma-Louise  Campbell
  Address Institute for Biomedical Research into Human Movement and Health
Manchester Metropolitan University
Room T1.01
John Dalton Tower
Oxford Road
  City/town Manchester
  Zip/Postcode M1 5GD
  Country United Kingdom
  Tel +44 (0)161 2475950
  Email e.campbell@mmu.ac.uk
Sponsor Barts and the London School of Medicine (UK)
  Address c/o Mrs Gayle Maffulli
Centre for Sports and Exercise Medicine
Barts and the London School of Medicine
Mile End Hospital
Bancroft Road
  City/town London
  Zip/Postcode E1 4DG
  Country United Kingdom
  Tel +44 (0)20 82238839
  Fax +44 (0)20 82238930
  Email g.maffulli@qmul.ac.uk
Date applied 15/02/2010
Last edited 17/03/2010
Date ISRCTN assigned 17/03/2010
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central